Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Shaperon Enrolls First Patient in Phase 2 U.S. Trial for Atopic Dermatitis Therapy 'Nugel'
Details : NuGel® is a gel type atopic dermatitis drug candidate, inhibiting NLRP3 inflammasome through GPCR19-P2X7 modulation. Its active pharmaceutical ingredient called HY209.
Brand Name : Nugel
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2024
Lead Product(s) : Taurodeoxycholic Acid
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?